Diastolic heart failure: Mechanisms and controversies

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 7, 2008, Pages 375-386

  Ouzounian, Maral ^a   Lee, Douglas S ^b   Liu, Peter P ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; CANDESARTAN; COLLAGEN; CONNECTIN; DIGOXIN; DIURETIC AGENT; IRBESARTAN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PARVALBUMIN; PERINDOPRIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RHO KINASE INHIBITOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SILDENAFIL; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA ANTAGONIST;

AGING; CLINICAL ASSESSMENT; CLINICAL TRIAL; CYTOSKELETON; DIABETES MELLITUS; DIASTOLIC HEART FAILURE; DIFFERENTIAL DIAGNOSIS; DRUG TARGETING; EPIDEMIOLOGICAL DATA; EXTRACELLULAR MATRIX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LUNG CONGESTION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SURVIVAL RATE; SYSTOLIC HEART FAILURE;

AGING; DIABETES MELLITUS; DIAGNOSIS, DIFFERENTIAL; HEART FAILURE, DIASTOLIC; HUMANS; HYPERTENSION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; STROKE VOLUME;

EID: 46649112296     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1245     Document Type: Review

References (82)

1. Fishberg AM (1937) Heart Failure. Philadelphia: Lea & Febiger
2. Aurigemma GP et al. (2006) Contractile behavior of the left ventricle in diastolic heart failure: With emphasis on regional systolic function. Circulation 113: 296-304
3. Borbély A et al. (2005) Cardiomyocyte stiffness in diastolic heart failure. Circulation 111: 774-781
4. van Heerebeek L et al. (2006) Myocardial structure an function differ in systolic and diastolic heart failure. Circulation 113 1966-1973
5. Nagueh SF et al. (2004) Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation 110: 155-162
6. Neagoe C et al. (2002) Titin isoform switch in ischemic human heart disease. Circulation 106: 1333-1341
7. Heymans S et al. (2005) Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112 1136-1144
8. Ahmed SH et al. (2006) Matrix metalloproteinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113: 2089-2096
9. Carson P et al.; for the I-PRESERVE Investigators (2005) The irbesartan in heart failure with preserved design. J Card Fall 11: 576-585
10. Yusuf S et al.; CHARM Investigators and Committees (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 362: 777-781
11. Paulus WJ et al. (2007) How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28: 2539-2550
12. Solomon SD et al.; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators (2005) Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112: 3738-3744
13. Skaluba SJ and Litwin SE (2004) Mechanisms of exercise intolerance: insights from tissue Doppler imaging. Circulation 109: 972-977
14. Yip G et al. (2002) Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: Time for a redefinition? Heart 87: 121-125
15. Yu CM et al. (2002) Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 105: 1195-1201
16. Petrie MC et al. (2002) "Diastolic heart failure" or heart failure caused by subtle left ventricular systolic dysfunction? Heart 87: 29-31
17. Nikitin NP et al. (2002) Color tissue Doppler-derived long-axis left ventricular function in heart failure with preserved global systolic function. Am J Cardiol 90: 1174-1177
18. Wang J et al. (2007) Systolic and diastolic dyssynchrony in patients with diastolic heart failure and the effect of medical therapy. J Am Coll Cardiol 49: 88-96
19. Yu CM et al. (2007) Diastolic and systolic asynchrony in patients with diastolic heart failure: A common but ignored condition. J Am Coll Cardiol 49: 97-105
20. Sliwa K et al. (2005) Epidemiology and etiology of cardiomyopathy in Africa. Circulation 112: 3577-3583
21. Rame JE et al. (2004) Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. Am J Cardiol 93: 234-237
22. Owan TE and Redfield MM (2005) Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 47: 320-332
23. Packer M (1990) Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure. Circulation 81: 11178-11186
24. Lee DS and Vasan RS (2005) Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 20: 201-210
25. Hunt SA et al. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-e235
26. Vasan RS and Levy D (2000) Defining diastolic heart failure: A call for standardized diagnostic criteria. Circulation 101: 2118-2121
27. Zile MR et al. (2001) Heart failure with a normal ejection fraction: Is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 104: 779-782
28. Zile MR et al. (2004) Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350: 1953-1959
29. Gandhi SK et al. (2001) The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344: 17-22
30. Cleland JG et al. (2007) Prognosis in heart failure with a normal ejection fraction. N Engl J Med 357: 829-830
31. Vasan RS et al. (1995) Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol 26: 1565-1574
32. Owan TE et al. (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355: 251-259
33. Bhatia RS et al. (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 260-269
34. Gilman G et al. (2007) Diastolic function: A sonographer's approach to the essential echocardiographic measurements of left ventricular diastolic function. J Am Soc Echocardiogr 20: 199-209
35. Dokainish H et al. (2004) Optimal noninvasive assessment of left ventricular filling pressures: A comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 109: 2432-2439
36. Hillis GS et al. (2004) Noninvasive estimation of left ventricular filling pressure by E/e' is a powerful predictor of survival after acute myocardial infarction. J Am Coll Cardiol 43: 360-367
37. Pritchett AM et al. (2005) Diastolic dysfunction and left atrial volume: A population-based study. J Am Coll Cardiol 45: 87-92
38. Tsang TS et al. (2003) Prediction of risk for first age-related cardiovascular events in an elderly population: The incremental value of echocardiography. J Am Coll Cardiol 42: 1199-1205
39. Periasamy M et al. (1999) Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene. J Biol Chem 274 2556-2562
40. Muller OJ et al. (2003) Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload. Cardiovasc Res 59: 380-389
41. MacLennan DH and Kranias EG (2003) Phospholamban: A crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 4: 566-577
42. Luo W et al. (1994) Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 75: 401-409
43. Chu G et al. (1997) Monomeric phospholamban overexpression in transgenic mouse hearts. Circ Res 81: 485-492
44. Periasamy M and Huke S (2001) SERCA pump level is a critical determinant of Ca(2+)homeostasis and cardiac contractility. J Mol Cell Cardiol 33: 1053-1063
45. Cain BS et al. (1998) Human SERCA2a levels correlate inversely with age in senescent human myocardium. J Am Coll Cardiol 32 458-467
46. Piccini JP et al. (2004) New insights into diastolic heart failure: Role of diabetes mellitus. Am J Med 116 (suppl 5A): S64-S75
47. Flesch M et al. (1997) Contractile systolic and diastolic dysfunction in renin-induced hypertensive cardiomyopathy. Hypertension 30: 383-391
48. Studeli R et al. (2006) Diastolic dysfunction in human cardiac allografts is related with reduced SERCA2a gene expression. Am J Transplant 6: 775-782
49. Wolska BM et al. (2001) Expression of slow skeletal troponin I in adult transgenic mouse heart muscle reduces the force decline observed during acidic conditions. J Physiol 536: 863-870
50. Takimoto E et al. (2004) Frequency- and afterload-dependent cardiac modulation in vivo by troponin I with constitutively active protein kinase A phosphorylation sites. Circ Res 94: 496-504
51. Vahebi S et al. (2005) Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin. Circ Res 96: 740-747
52. Tian R et al. (1997) Role of MgADP in the development of diastolic dysfunction in the intact beating rat heart. J Clin Invest 99 745-751
53. Bronzwaer JG and Paulus WJ (2005) Matrix, cytoskeleton, or myofilaments: which one to blame for diastolic left ventricular dysfunction? Prog Cardiovasc Dis 47: 276-284
54. Yamamoto K et al. (2002) Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 55: 76-82
55. Wu Y et al. (2000) Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol Cell Cardiol 32: 2151-2162
56. Aronson D (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21: 3-12
57. Martos R et al. (2007) Diastolic heart failure: Evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 115: 888-895
58. Granzier H et al. (2005) Titin: Physiological function and role in cardiomyopathy and failure. Heart Fail Rev 10: 211-223
59. Radke MH et al. (2007) Targeted deletion of titin N2B region leads to diastolic dysfunction and cardiac atrophy. Proc Natl Acad Sci USA 104: 3444-3449
60. van Heerebeek L et al. (2006) Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113 1966-1973
61. Yamasaki R et al. (2002) Protein kinase A phosphorylates titin's cardiac-specific N2B domain and reduces passive tension in rat cardiac myocytes. Circ Res 90: 1181-1188
62. Aronow WS (2003) Effects of aging on the heart. In Brocklehurst's Textbook of Geriatric Medicine and Gerontology, 341-348 (Eds Tallis RC and Fillit HM) Edinburgh: Churchill Livingstone
63. Corral-Debrinski M et al. (1991) Hypoxemia is associated with mitochondrial DNA damage and gene induction: Implications for cardiac disease. JAMA 266: 1812-1816
64. Olivetti G et al. (1991) Cardiomyopathy of the aging human heart: myocyte loss and reactive cellular hypertrophy. Circ Res 68: 1560-1568
65. Kai H et al. (2005) Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 28: 483-490
66. Perticone F et al. (1999) Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. Circulation 99: 1991-1996
67. Brush JE Jr. et al. (1988) Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 319: 1302-1307
68. Lamb HJ et al. (1999) Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99: 2261-2267
69. Leite-Moreira AF et al. (1999) Afterload induced changes in myocardial relaxation: A mechanism for diastolic dysfunction. Cardiovasc Res 43: 344-353
70. Kawaguchi M et al. (2003) Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations. Circulation 107: 714-720
71. Lam CS et al. (2007) Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115: 1982-1990
72. Liu JE et al. (2001) The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: The Strong Heart Study. J Am Coll Cardiol 37: 1943-1949
73. Liu JE et al. (2003) Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: The Strong Heart Study. J Am Coll Cardiol 41: 2022-2028
74. Paulus WJ et al. (1994) Different effects of "supply" and "demand" ischemia on left ventricular diastolic function in humans. In Left Ventricular Diastolic Dysfunction and Heart Failure, 286-305 (Eds Gaasch WH and LeWinter MM) Philadelphia: Lea & Febiger
75. Cleland JG et al.; PEP-CHF Investigators (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27: 2338-2345
76. Ahmed A et al. (2006) Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary digitalis investigation group trial. Circulation 114: 397-403
77. Higashi M et al. (2003) Long-term inhibition of Rhokinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: Effect on endothelial NAD(P)H oxidase system. Circ Res 93: 767-775
78. Takimoto E et al. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11: 214-222
79. Kuwahara F et al. (2002) Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106: 130-135
80. Little WC et al. (2005) The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11 191-195
81. Hirsch JC et al. (2004) Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction. Am J Physiol Heart Circ Physiol 286: H2314-H2321
82. Huq F et al. (2004) Gene transfer of parvalbumin improves diastolic dysfunction in senescent myocytes. Circulation 109 2780-2785